Exploiting antitumor immunity to overcome relapse and improve remission duration

Cancer Immunology, Immunotherapy

Volumn 61, Issue 7, 2012, Pages 1113-1124

  Chen, Lei L ^a   Chen, Xinjian ^a   Choi, Haesun ^b   Sang, Hongxun ^c   Chen, Leo C ^d   Zhang, Hongbo ^e   Gouw, Launce ^a   Andtbacka, Robert H ^a   Chan, Benjamin K ^f   Rodesch, Christopher K ^f   Jimenez, Arnie ^g   Cano, Pedro ^b   Jones, Kimberly A ^a   Oyedeji, Caroline O ^b   Martins, Tom ^h   Hill, Harry R ^h   Schumacher, Jonathan ^h   Willmore, Carlynn ^h   Scaife, Courtney L ^a   Ward, John H ^a   Morton, Kathryn ^a   Lor Randall, R ^a   Lazar, Alexander J ^b   Patel, Shreyaskumar ^b   Trent, Jonathan C ^b   Frazier, Marsha L ⁱ   Lin, Patrick ^b   Jensen, Peter ^a   Benjamin, Robert S ^b   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e XI'AN JIAOTONG UNIVERSITY   (China)

^f UNIVERSITY OF UTAH   (United States)

^g Vel Lab Research   (United States)

^h ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

Author keywords

GIST; IFN ; IFN ; Imatinib; Immunotherapy; Peginterferon 2b

Indexed keywords

DOXORUBICIN; GAMMA INTERFERON; IFOSFAMIDE; IMATINIB; PEGINTERFERON ALPHA2B;

ADAPTIVE IMMUNITY; ADJUVANT CHEMOTHERAPY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INNATE IMMUNITY; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; NATURAL KILLER CELL; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYNOVIAL SARCOMA; TH1 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-GAMMA; LYMPHOCYTES; MIDDLE AGED; PIPERAZINES; POLYETHYLENE GLYCOLS; PYRIMIDINES; RECOMBINANT PROTEINS; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862761207     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1185-1     Document Type: Article

References (45)

1. WH Fridman B Mlecnik G Bindea F Pagès J Galon 2011 Immunosurveillance in human non-viral cancers Curr Opin Immunol 23 272 278 21237631 10.1016/j.coi.2010.12.011 1:CAS:528:DC%2BC3MXkt1Kitrs%3D
2. V Shankaran H Ikeda AT Bruce JM White PE Swanson LJ Old, et al. 2001 IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107 1111 11323675 10.1038/35074122 1:CAS:528:DC%2BD3MXjsVCrtr4%3D
3. GP Dunn CM Koebel RD Schreiber 2006 Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 836 848 17063185 10.1038/nri1961 1:CAS:528:DC%2BD28XhtFWns7fK
4. AS Dighe E Richards LJ Old RD Schreiber 1994 Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors Immunity 1 447 456 7895156 10.1016/1074-7613(94)90087-6 1:CAS:528:DyaK2cXmt1yntro%3D
5. C Becker H Pohla B Frankenberger T Schüler M Assenmacher DJ Schendel, et al. 2001 Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay Nat Med 7 1159 1162 11590442 10.1038/nm1001-1159 1:CAS:528:DC%2BD3MXns12rsrc%3D
6. JR Schoenborn CB Wilson 2007 Regulation of interferon-gamma during innate and adaptive immune responses Adv Immunol 96 41 101 17981204 10.1016/S0065-2776(07)96002-2 1:CAS:528:DC%2BD1cXhs1ajtbw%3D
7. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 267 296 17134371 10.1146/annurev.immunol.25.022106.141609 1:CAS:528:DC%2BD2sXltlagu7c%3D
8. ES Trombetta I Mellman 2005 Cell biology of antigen processing in vitro and in vivo Annu Rev Immunol 23 975 1028 15771591 10.1146/annurev.immunol.22. 012703.104538 1:CAS:528:DC%2BD2MXktFOisr4%3D
9. N Kadowaki S Antonenko JY Lau YJ Liu 2000 Natural interferon alpha/beta-producing cells link innate and adaptive immunity J Exp Med 192 219 226 10899908 10.1084/jem.192.2.219 1:CAS:528:DC%2BD3cXkvFGiu74%3D
10. B Reizis A Bunin HS Ghosh KL Lewis V Sisirak 2011 Plasmacytoid dendritic cells: recent progress and open questions Annu Rev Immunol 29 163 183 21219184 10.1146/annurev-immunol-031210-101345 1:CAS:528:DC%2BC3MXltlKns7w%3D
11. P Rizza I Capone F Moretti E Proietti F Belardelli 2011 IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use Expert Rev Vaccines 10 487 498 21506646 10.1586/erv.11.9 1:CAS:528:DC%2BC3MXkvF2itbk%3D
12. RJ Critchley-Thorne DL Simons N Yan AK Miyahira FM Dirbas DL Johnson, et al. 2009 Impaired interferon signaling is a common immune defect in human cancer Proc Natl Acad Sci USA 106 9010 9015 19451644 10.1073/pnas.0901329106 1:CAS:528:DC%2BD1MXntlyiu7Y%3D
13. Narumi K, Udagawa T, Kondoh A, Kobayashi A, Hara H, Ikarashi Y, et al. (2011) In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther, doi: 10.1038/gt.2011.73
14. AG Sikora N Jaffarzad Y Hailemichael A Gelbard SW Stonier KS Schluns, et al. 2009 IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity J Immunol 182 7398 7407 19494262 10.4049/jimmunol.0802982 1:CAS:528:DC%2BD1MXmslCnsro%3D
15. ME Miquilena-Colina T Lozano-Rodríguez L García-Pozo A Sáez P Rizza I Capone, et al. 2009 Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial Vaccine 27 5654 5660 19635606 10.1016/j.vaccine.2009.07.014 1:CAS:528:DC%2BD1MXhtVKntrrP
16. KW Hance CJ Rogers DA Zaharoff D Canter J Schlom JW Greiner 2009 The antitumor and immunoadjuvant effects of IFN-α in combination with recombinant poxvirus vaccines Clin Cancer Res 15 2387 2396 19276249 10.1158/1078-0432.CCR-08-1752 1:CAS:528:DC%2BD1MXjvVWlu7k%3D
17. Y Ma R Conforti L Aymeric C Locher O Kepp G Kroemer, et al. 2011 How to improve the immunogenicity of chemotherapy and radiotherapy Cancer Metastasis Rev 30 71 82 21298323 10.1007/s10555-011-9283-2 1:CAS:528:DC%2BC3MXitlKltLY%3D
18. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. (2002) Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38(Suppl 5):S19-S27
19. JC McAuliffe KK Hunt AJ Lazar H Choi W Qiao P Thall, et al. 2009 A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis Ann Surg Oncol 16 910 919 18953611 10.1245/s10434-008-0177-7
20. M Ayyoub RN Taub ML Keohan M Hesdorffer G Metthez L Memeo, et al. 2004 The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma Cancer Immunol 4 7 20
21. M Debiec-Rychter R Sciot A Le Cesne M Schlemmer P Hohenberger AT van Oosterom, et al. 2006 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 1093 1103 16624552 10.1016/j.ejca.2006.01.030 1:CAS:528:DC%2BD28Xks1ertb0%3D
22. MC Heinrich K Owzar CL Corless D Hollis EC Borden CD Fletcher, et al. 2008 Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 5360 5367 18955451 10.1200/JCO.2008.17.4284 1:CAS:528:DC%2BD1MXhslCmug%3D%3D
23. LL Chen JA Holden H Choi J Zhu EF Wu KA Jones, et al. 2008 Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression Mod Pathol 21 826 836 18488000 10.1038/modpathol.2008.46 1:CAS:528:DC%2BD1cXnsFOhuro%3D
24. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 70 83 17193820 10.1053/j.semdp.2006.09.001
25. LL Chen JC Trent EF Wu GN Fuller L Ramdas W Zhang, et al. 2004 A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 5913 5919 15342366 10.1158/0008-5472.CAN-04-0085 1:CAS:528:DC%2BD2cXntFClsr4%3D
26. SR McLean M Gana-Weisz B Hartzoulakis R Frow J Whelan D Selwood, et al. 2005 Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala Mol Cancer Ther 4 2008 2037 16373716 10.1158/1535-7163.MCT-05-0070 1:CAS:528:DC%2BD2MXhtlCnsrjJ
27. MC Heinrich CL Corless CD Blanke GD Demetri H Joensuu PJ Roberts, et al. 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 4774 16954519 10.1200/JCO.2006.06.2265 1:CAS:528:DC%2BD28XhtFynsrrN
28. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 12181401 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D
29. J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 15451219 10.1016/S0140-6736(04) 17098-0 1:CAS:528:DC%2BD2cXnvVOiu7o%3D
30. S Patel JR Zalcberg 2008 Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials Eur J Cancer 44 501 509 18234488 10.1016/j.ejca.2007.11.021 1:CAS:528:DC%2BD1cXjtlWisr0%3D
31. JY Blay A Le Cesne I Ray-Coquard B Bui F Duffaud C Delbaldo, et al. 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 1107 1113 17369574 10.1200/JCO.2006.09.0183 1:CAS:528:DC%2BD2sXksVyrs7s%3D
32. C Borg M Terme J Taieb C Ménard C Flament C Robert, et al. 2004 Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects J Clin Invest 114 379 388 15286804 1:CAS:528:DC%2BD2cXmtlynsrc%3D
33. C Ménard JY Blay C Borg S Michiels F Ghiringhelli C Robert, et al. 2009 Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients Cancer Res 69 3563 3569 19351841 10.1158/0008-5472.CAN-08-3807
34. P Ray N Krishnamoorthy TB Oriss A Ray 2010 Signaling of c-kit in dendritic cells influences adaptive immunity Ann N Y Acad Sci 1183 104 122 20146711 10.1111/j.1749-6632.2009.05122.x 1:CAS:528:DC%2BC3cXisVehs7w%3D
35. Balachandran1 VP, Cavnar1 MJ, Zeng1 S, Bamboat1 ZM, Ocuin1 LM, Obaid1 H, et al. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17:1094-1100
36. RM Bukowski C Tendler D Cutler E Rose MM Laughlin P Statkevich 2002 Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation Cancer 95 389 396 12124839 10.1002/cncr.10663 1:CAS:528:DC%2BD38Xmt1ehtbs%3D
37. Y Sato Y Nabeta T Tsukahara Y Hirohashi R Syunsui A Maeda, et al. 2002 Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma J Immunol 169 1611 1618 12133991 1:CAS:528:DC%2BD38XlslWhtb8%3D
38. TG Berger B Feuerstein E Strasser U Hirsch D Schreiner G Schuler, et al. 2002 Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories J Immunol Methods 268 131 140 12215381 10.1016/S0022-1759(02)00189-8 1:CAS:528:DC%2BD38Xms1yitrg%3D
39. LC Chen JC Delgado PE Jensen X Chen 2009 Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application J Immunol 183 4094 4102 19684083 10.4049/jimmunol. 0901081 1:CAS:528:DC%2BD1MXhtVOmu7rO
40. P Cano B Fan 2001 A geometric and algebraic view of MHC-peptide complexes and their binding properties BMC Struct Biol 1 2 15 11472639 10.1186/1472-6807-1-2 1:STN:280:DC%2BD3srgs1Crsw%3D%3D
41. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782 10673991 10.1016/S0959- 8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D
42. RS Benjamin H Choi HA Macapinlac MA Burgess SR Patel LL Chen, et al. 2007 We should desist using RECIST, at least in GIST J Clin Oncol 25 1760 1764 17470866 10.1200/JCO.2006.07.3411
43. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel, et al. 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 17470865 10.1200/JCO.2006.07.3049
44. ® [prescribing information] (2008) Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
45. C Preudhomme J Guilhot FE Nicolini A Guerci-Bresler F Rigal-Huguet F Maloisel, et al. 2010 Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2511 2521 21175313 10.1056/NEJMoa1004095 1:CAS:528:DC%2BC3cXhs1Whsb%2FI